Nitazoxanide: a new broad spectrum antiparasitic agent

References

• White AC Jr. The disappearing arsenal of antiparasitic drugs. N Engl. J Med. 343, 1273–1274 (2000).
   PubMed Web of Science ®Google Scholar
• White AC Jr. Nitazoxanide: an important advance in antiparasitic therapy. Am. J.Trop. Med. Hyg. 68,382–283 (2003).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hyrnenolepis nana infections. Am.j Trop. Med. Hyg. 33, 511–512 (1984).
   PubMed Web of Science ®Google Scholar
• Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. 18,95–97 (2002).
   PubMed Web of Science ®Google Scholar
• Stockis A, Allemon AM, De Bruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int. JPharrnacol. Ther. 40,213–220 (2002).
   Google Scholar
• Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JE Nitazoxanide: pharmacokinetics and metabolism in man. Int. J Clin. Pharmacol Ther. 38, 387–394 (2000).
   PubMed Web of Science ®Google Scholar
• Stockis A, De Bruyn S, Gengler C, Rosillon D. Nitazoxanidepharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. mt. J Clin. Pharrnacol. Ther. 40, 221–227 (2002).
   Web of Science ®Google Scholar
• Rossignol JF, Hidalgo H, Feregrino M, et al. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 92, 663–666 (1998).
   PubMed Web of Science ®Google Scholar
• •Controlled trial demonstrated significant activity in cryptosporidiosis amoung HIV patients with CD4 cell counts of more than 50/mm3.
   Google Scholar
• Theodos CM, Griffiths JK, d'Onfro J, Fairfield A, Tzipori S. Efficacy of nitazoxanide against Cryptosporidium par V11117 in cell culture and in animal models. Antimicrob. Agents Chemother. 42, 1959–1965 (1998).
   PubMed Web of Science ®Google Scholar
• Giacometti A0, Barchiesi F, Ancarani F, Scalise G, Cirioni. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidiumparvuni in cell culture. J Antimicrob. Chemother. 45, 453–456 (2000).
   PubMed Web of Science ®Google Scholar
• Gargala G, Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium par V11117 development in sporozoite-infected HCT-8 enterocytic cells. J Antimicrob. Chemother. 46, 57–60 (2000).
   PubMed Web of Science ®Google Scholar
• Blagburn BL, Drain KL, Land TM, et al. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrob. Agents Chemother. 42, 2877–2882 (1998).
   PubMed Web of Science ®Google Scholar
• Li X, Brasseur P, Agnamey P, etal. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitol. (Praha)50, 19–22 (2003).
   Google Scholar
• Doumbo O, Rossignol JF, Pichard E, etal. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. j Trop. Med. Hyg. 56, 637–939 (1997).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect. Dis. 184, 103–106 (2001).
   PubMed Web of Science ®Google Scholar
• •This controlled trial demonstrated activity in cryptosporidiosis in normal children and adults.
   Google Scholar
• Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375–1380 (2002).
   PubMed Web of Science ®Google Scholar
• ••Pivotal study demonstrated improvementin clinical resolution, parasitologic response, and survival amoung malnourished children with cryptosporidiosis. However, there was no significant response to the dose used in malnourished children with HIV.
   Google Scholar
• Brantley RK, Williams KR, Silva TM, et al. AIDS-associated diarrhea and wasting in northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Brazil J. Infect. Dis. 7, 16–22 (2003).
   PubMedGoogle Scholar
• Maggi P, Larocca AM, Ladisa N, etal. Opportunistic parasitic infections of the intestinal tract in the era of highly active antiretroviral therapy: is the CD4+ count so important? Clin. Infect. Dis. 33, 1609–1611 (2001).
   PubMed Web of Science ®Google Scholar
• •Noted an excellent response in AIDs patients with cryptosporidiosis to combined therapy with paromomycin and anti-retroviral therapy.
   Google Scholar
• Okhuysen PC, Robinson P, Nguyen MT, et al. Jejunal cytokine response in AIDS patients with chronic cryptosporidiosis and during immune reconstitution. AIDS 15, 802–804 (2001).
   PubMed Web of Science ®Google Scholar
• •Demonstrates an excellent response in AIDS patients with cryptosporidiosis to combined therapy with paromomycin and antiretroviral therapy.
   Google Scholar
• Vasquez TO, Alvarez Ch R, Gonzales SN, et al. [Diagnosis and treatment of cyclospora cayetanensisinfection in paediatric patients]. Rev Gastroenterol Peru 18, 116–120 (1998).
   PubMedGoogle Scholar
• Diaz E, Mondragon J, Ramirez E, Bernal R. Short report: epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am. j Trop. Med. Hyg. 68, 384–385 (2003).
   PubMed Web of Science ®Google Scholar
• Romero Cabello R, Guerrero LR, Munoz Garcia MR, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. 91, 701–703 (1997).
   PubMed Web of Science ®Google Scholar
• •This large open-label study demonstrated clinical and parasitologic responses of intestinal protozoans and helminths to nitazoxanide.
   Google Scholar
• Bialek R, Overkamp D, Rettig I, Knobloch J. Case report: nitazoxanide treatment failure in chronic isosporiasis. Am. j Trop. Med. Hyg. 65, 94–95 (2001).
   PubMed Web of Science ®Google Scholar
• Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entarnoeba histolytica and Trichornonas vagina/is. j Antimicrob. Chemother. 49, 103–111 (2002).
   PubMed Web of Science ®Google Scholar
• Cedillo-Rivera RB, Gonzalez-Robles A, Tapia A, Yepez-Mulia L, Chavez. In vitro effect of nitazoxanide against Entarnoeba histolytica, Giardia intestinalis and 7iichornonas vaginalistrophozoites. Eukaryot. Microbiol 49, 201–208 (2002).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entarnoeba histolytica or E. dispar a randomized, double-blind, placebo-controlled study of nitazoxanide. Infect. Dis. 184, 381–384 (2001).
   Web of Science ®Google Scholar
• •Demonstratedsthe parasitologic and clinical efficacy of nitazoxanide in giardiasis.
   Google Scholar
• Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment. Pharmacol Ther. 15, 1409–1415 (2001).
   PubMed Web of Science ®Google Scholar
• •Demonstrates the parasitologic and clinical efficacy of nitazoxanide in giardiasis.
   Google Scholar
• Abboud P, Lemee V, Gargala G, et al. Successful treatment of metronidazole-and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Cilia. Infect. Dis. 32, 1792–1794 (2001).
   PubMed Web of Science ®Google Scholar
• Bicart-See A, Massip P, Linas MD, Datry A. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob. Agents Chemother. 44, 167–168 (2000).
   PubMed Web of Science ®Google Scholar
• Abaza H, El-Zayadi AH, Kabil SM, Rizk H. Nitazoxanide in the treatment of patients with intestinal protozoan and helminth infections: a report on 546 patients in Egypt. Carr. Ther. Res. 58, 116–121 (1998).
   Google Scholar
• •This large open-label study demonstrated the clinical and parasitologic efficacy of nitazoxanide in intestinal helminth infections.
   Google Scholar
• Davila-Gutierrez CEC, Trujillo-Hernandez B, Huerta M, Vasquez. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am. j Trop. Med. Hyg. 66, 251–254 (2002).
   PubMed Web of Science ®Google Scholar
• •A controlled trial demonstrating that nitazoxanide is as effective as melbendazole or albendazole against intestinal nematodes and as praziquantel for the Hymenolepis.
   Google Scholar
• Ortiz JJ, Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans. R. Soc. Trop. Med. Hyg. 96, 193–196 (2002).
   PubMed Web of Science ®Google Scholar
• •Further evidence that nitazoxanide is as effective as melbendazole or albendazole against intestinal nematodes and as praziquantel for the Hymenolepis.
   Google Scholar
• Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob. Agents Chernother. 47, 467–474 (2003).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans. R. Soc. Trop. Med. Hyg. 92, 103–104 (1998).
   PubMed Web of Science ®Google Scholar
• Favennec L, Jaye Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment. Pharrnacol. Ther. 17, 265–270 (2003).
   Google Scholar
• Mifian JC, Mull R, Freise S, Richter J. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Easciola hepatica infection. Am. J. Trop. Med. Hyg. 63, 264–269 (2000).
   PubMed Web of Science ®Google Scholar
• Graham CS, Brodie SB, Weller PE Imported Easciola hepatica infection in the United States and treatment with triclabendazole. Clin. Infect. Dis. 33, 1–5 (2001).
   PubMed Web of Science ®Google Scholar
• Dubreuil L, Houcke I, Mouton Y, Rossignol JE In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antirnicrob. Agents Chernother. 40, 2266–2270 (1996).
   PubMed Web of Science ®Google Scholar
• McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antirnicrob. Agents Chernother. 44, 2254–2258 (2000).
   Google Scholar
• •An in vitro and in vivo animal study suggesting that nitazoxanide may be useful in Clostridium difficile colitis.
   Google Scholar
• Megraud F, Occhialini A, Rossignol JE Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antirnicrob. Agents Chernother. 42, 2836–2840 (1998).
   PubMed Web of Science ®Google Scholar
• •An initial study into nitazoxanide for Helicobacter eradication.
   Google Scholar
• Yamamoto Y, Hakki A, Friedman H, etal. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an ann-Helicobacter pylori agent with antivacuolating toxin activity. Chemotherapy 45, 303–312 (1999).
   PubMed Web of Science ®Google Scholar